非小细胞肺癌的生物治疗研究进展

Biotherapy Progress in the Treatment for Non-small Cell Lung Cancer

肺癌是恶性肿瘤相关死亡的首要原因之一,发病率在多数国家仍在上升,特别是发达和发展中国家。肺癌分为非小细胞肺癌(NSCLC)和小细胞肺癌(SCLC)两大类。其中,NSCLC约占肺癌总发生率的85%;大部分患者发现时已属于晚期,常规治疗有一定局限性,疗效不理想。近年来,生物治疗包括靶向治疗、树突状细胞、肿瘤疫苗(DC肿瘤疫苗)等在NSCLC临床研究与应用中取得可喜进展,本文就近年来NSCLC的生物治疗方面作一综述。

Lung cancer is the leading cause of malignancy-related death. The incidence rate is still rising in most countries,especially in the developed and developing countries. Lung cancer can be divided into two categories： non-small cell lung cancer （NSCLC） and small cell lung cancer （SCLC）. NSCLC accounted for about 85% of the total incidence of lung cancer.For the certain limitations of conventional treatment,the clinical response was unsatisfactory. In recent years,biological treatment including targeting therapy,dendritic cells,tumor vaccine（DC tumor vaccine） in the clinical research and applications of NSCLC made gratifying progress. In this article the progress in biological treatment for NSCLC is reviewed.